Palatin Technologies And King Pharmaceuticals Announce Plan To Present Results Of Bremelanotide Phase 2b Studies In Men With Erectile Dysfunction

Palatin Technologies, Inc. (Amex: PTN) and King Pharmaceuticals, Inc. (NYSE: KG) today announced plans to present the results from two bremelanotide Phase 2b studies of men with erectile dysfunction (ED). The presenters are Jed Kaminetsky, MD, Clinical Assistant Professor, Department of Urology, NYU School of Medicine; Stanley E. Althof, PhD, Professor of Psychology, Case Western Reserve School of Medicine and Christopher Steidle, MD, Clinical Associate Professor of Urology, Indiana University School of Medicine. The companies plan to present the results at the American Urological Association (AUA) Annual Meeting in Anaheim, CA, which takes place May 19-24, 2007. The Phase 2b studies were designed to evaluate the safety and efficacy of bremelanotide for the treatment of male ED using a range of intranasally administered doses in an at-home environment. A total of 726 and 294 patients were enrolled in a non-diabetic ED patient study and a diabetic ED patient study, respectively. Palatin and King announced initial positive results from the Phase 2b trial evaluating bremelanotide for the treatment of male non- diabetic ED patients in November 2006. Dr. Kaminetsky's presentation, titled "Phase 2b Study of Bremelanotide in the Treatment of ED in Non-Diabetic Males," and Dr. Althof's presentation, titled "Improvement in Sexual Relationship Satisfaction, Confidence, and Self- Esteem in ED Patients Treated with Bremelanotide," will be presented at a podium session titled "Sexual Function/Dysfunction/Andrology: Evaluation (II)" on Monday, May 21st at 1:00 PM PDT. Dr. Steidle's poster, titled "Phase 2b Study of Bremelanotide in the Treatment of ED in Diabetic Males," will be presented at a poster session titled "Sexual Function/Dysfunction/Andrology: Surgical, Medical and Non-surgical Therapy (II)" from 3:30 PM - 5:30 PM PDT on Monday, May 21st. About ED ED is defined as the consistent inability to attain and maintain an erection sufficient for sexual intercourse. The condition is correlated with increasing age, cardiovascular disease, hypertension, diabetes, hyperlipidemia, and smoking. In addition, certain prescription drugs and psychogenic issues may contribute to ED. It is estimated that some degree of ED affects one half of all men over the age of 40 and that 150 million men worldwide suffer from ED. About Palatin Technologies, Inc. Palatin Technologies, Inc. is a biopharmaceutical company focused on discovering and developing targeted, receptor-specific small molecule and peptide therapeutics. Palatin's lead product candidate, bremelanotide, is currently in Phase 2 clinical trials for both male and female sexual dysfunction. Palatin's internal research and development capabilities, anchored by its proprietary MIDAS(TM) technology, are fueling product development. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. To date, Palatin has entered into collaborations with AstraZeneca, King Pharmaceuticals, and Tyco Healthcare Mallinckrodt. For additional information regarding Palatin, please visit Palatin Technologies' website at

(Author: http://www.palatin.com)

<< Prev	Pharmacy News Home	Next>>